Apogee Therapeutics, Inc.

NasdaqGM:APGE Stock Report

Market Cap: US$2.7b

Apogee Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Apogee Therapeutics has a total shareholder equity of $734.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $776.3M and $41.9M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$526.05m
EquityUS$734.40m
Total liabilitiesUS$41.88m
Total assetsUS$776.29m

Recent financial health updates

Recent updates

We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate

Nov 14
We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis

Nov 10

We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate

Jun 20
We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate

Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

Jun 18

We're Interested To See How Apogee Therapeutics (NASDAQ:APGE) Uses Its Cash Hoard To Grow

Mar 05
We're Interested To See How Apogee Therapeutics (NASDAQ:APGE) Uses Its Cash Hoard To Grow

Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management

Mar 05

We're Not Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn

Nov 21
We're Not Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn

Financial Position Analysis

Short Term Liabilities: APGE's short term assets ($534.5M) exceed its short term liabilities ($32.6M).

Long Term Liabilities: APGE's short term assets ($534.5M) exceed its long term liabilities ($9.3M).


Debt to Equity History and Analysis

Debt Level: APGE is debt free.

Reducing Debt: APGE has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APGE has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: APGE has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 95.4% each year.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 04:36
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Apogee Therapeutics, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charlie YangBofA Global Research
Julian HarrisonBTIG
Edward NashCanaccord Genuity